Hugel Partners with Hans Biomed to Enter ECM Skin Booster Market

Secures Domestic Rights for ECM Product 'CellREDM' · HA Filler Combination Synergy Expected · External Collaboration Signals Portfolio Diversification

Finance|
|
By Lee Jung-min
||
null - Seoul Economic Daily Finance News from South Korea

Hugel (145020.KS), a global total medical aesthetics company, has secured domestic distribution rights for 'CellREDM™,' an extracellular matrix (ECM)-based product, expanding its portfolio.

Hugel announced on July 1 that it signed a domestic distribution agreement with Hans Biomed (042520.KS) for 'CellREDM.' Hans Biomed is the first company in Asia to receive establishment accreditation from the American Association of Tissue Banks (AATB). The AATB is a global standard organization that evaluates quality, safety, and ethical standards in the tissue banking field.

'CellREDM' is a product utilizing human acellular dermal matrix (hADM), a human tissue-derived material. It directly replenishes extracellular matrix components such as collagen and elastin to help restore skin structure. With this addition, Hugel now offers a comprehensive solution covering skin regeneration beyond its existing product lineup focused on wrinkle and volume improvement.

The agreement is significant in that Hugel, which has primarily built its business around in-house developed products, is now actively pursuing portfolio expansion through external collaboration. ECM products in particular are widely used in combination treatments with hyaluronic acid (HA) products, raising expectations for synergy with Hugel's existing flagship products.

The two companies plan to enhance product supply efficiency and pursue rapid market penetration through joint promotions and commercialization strategies tailored to the characteristics and specialties of clinics and hospitals.

"Based on our partnership with Hugel, we will promote the quality competitiveness of 'CellREDM,' which applies the proprietary tissue processing technology of Korea's first tissue bank, and actively highlight the product's strengths in reducing post-procedure downtime and pain," Hans Biomed CEO Kim Geun-young said.

"We plan to further solidify our leading position in the industry by responding swiftly to latent demand in the medical aesthetics market," Hugel CEO Jang Du-hyun said. "We will use this agreement as a starting point for Hugel's business expansion and continue to explore various business opportunities both domestically and internationally."

Original reporting by Lee Jung-min for Seoul Economic Daily.

AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.

Watch · Seoul Economic Daily

More →
5:11

AI KEY

Preview
Korean Corporate Intelligence HubKOSPI · KOSDAQ · 12 sectors

A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.

Korea Company Atlas

Preview
Market Ontology · The Feedback LoopKFTC 2025 · 92 groups · 121,954 articles

An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.

SIGNAL

Pre-register
English Edition · Capital MarketsM&A · IPO · PE · Fund Flows

Pre-register for SIGNAL English Edition — a premium subscription bringing Korean capital markets coverage (M&A, IPOs, private equity, fund flows) to global institutional investors. First access to the 50% introductory rate.